Original Article
A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2
N Engl J Med 1999; 341:1432-1438November 4, 1999
- Abstract
Background
Herpes simplex virus (HSV) infections are endemic, but the clinical characteristics of newly acquired HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections in adults have not been rigorously defined.
Methods
We monitored 2393 sexually active HSV-2–seronegative persons for clinical and serologic evidence of new HSV infection. Of the participants, 1508 were seropositive for HSV-1 and 885 were seronegative. Charts were reviewed in a blinded manner for classification of those with genitourinary or oropharyngeal symptoms. Charts were also reviewed for all 174 persons with HSV seroconversion.
Results
The rates of new HSV-1 and HSV-2 infections were 1.6 and 5.1 cases per 100 person-years, respectively. Of the 155 new HSV-2 infections, 57 (37 percent) were symptomatic, 47 of which (82 percent) were correctly diagnosed at presentation. Among the 74 patients given a clinical diagnosis of genital HSV-2 infection during the study, 60 were given a correct diagnosis and 14 were given an incorrect diagnosis, for a ratio of true positive results to false positive results of 4:1. Among the 98 persons with asymptomatic HSV-2 seroconversion, 15 percent had genital lesions at some time during follow-up. Women were more likely than men to acquire HSV-2 (P<0.01) and to have symptomatic infection. Previous HSV-1 infection did not reduce the rate of HSV-2 infection, but it did increase the likelihood of asymptomatic seroconversion, as compared with symptomatic seroconversion, by a factor of 2.6 (P<0.001). Of the 19 new HSV-1 infections, 12 were symptomatic. The rates of symptomatic genital HSV-1 infection and oropharyngeal HSV-1 infection were the same (0.5 case per 100 person-years).
Conclusions
Nearly 40 percent of newly acquired HSV-2 infections and nearly two thirds of new HSV-1 infections are symptomatic. Among sexually active adults, new genital HSV-1 infections are as common as new oropharyngeal HSV-1 infections.
Media in This Article
Figure 1
Serologically Documented Herpes Simplex Virus Type 2 (HSV-2) Infections.Table 1
Demographic and Serologic Characteristics of the Study Participants Who Acquired New Herpes Simplex Virus Infections.Article Activity
- Article
Herpes simplex virus (HSV) infections are endemic throughout the world.1-3 In both point-prevalence and prospective studies, a large percentage of persons who are seropositive for HSV type 1 (HSV-1) or HSV type 2 (HSV-2) have no clinical manifestations of the disease.3-6 Many of the clinical characteristics of symptomatic genital HSV are similar to those of other conditions, such as nongonococcal urethritis in men,7-10 nonchlamydial urethritis11 and recurrent vaginitis7 in women, and neurologic diseases, including aseptic meningitis.12,13 No studies have prospectively defined the relative frequency of symptomatic or asymptomatic HSV infection and the relative proportions of typical clinical manifestations of infection and atypical manifestations. In 1993 we initiated two parallel phase 3 trials of a glycoprotein-subunit vaccine against HSV-2 that was subsequently shown to be ineffective.14 These studies were conducted at 27 sites by clinicians experienced in the diagnosis and management of genital herpes.14 In this report we describe the clinical spectrum and course of the 155 new cases of HSV-2 infection and the 19 new cases of HSV-1 infection that occurred during these trials.
Methods
Study Participants
Sexually active adults who were seronegative for both HSV-2 and the human immunodeficiency virus were recruited into two similarly designed trials to evaluate the effectiveness of a glycoprotein-subunit vaccine for the prevention of HSV-2 infection. One trial, conducted at 18 centers, enrolled 531 HSV-2–seronegative persons, each of whom reported that he or she had been in an exclusive sexual relationship with a partner infected with HSV-2 for a minimum of six months. The second trial involved 22 clinics for the treatment of sexually transmitted diseases and enrolled 1862 persons who reported having had four or more sexual partners in the year before enrollment or who reported having one or more of the following sexually transmitted diseases: pelvic inflammatory disease (in women), a first episode of nongonococcal urethritis (in men), gonorrhea, chlamydia, primary or secondary syphilis, or trichomoniasis. The protocol was approved by the institutional review board at each of the study sites, and the participants gave written informed consent.
Study Design
The details of the study design and the overall outcomes of the trials have been reported elsewhere.14 In brief, the participants were randomly assigned to receive three immunizations with the recombinant glycoprotein-subunit gD2–gB2–MF59 HSV vaccine (Chiron, Emeryville, Calif.) or citrate buffer alone in MF59 adjuvant (placebo) and were followed at 11 routine visits at intervals of 2 weeks to 3 months during the 18-month study period.
All the participants received standardized counseling about the practice of safe sex at every scheduled study visit, including the recommendation to use condoms during each sexual exposure. The participants were instructed about the signs and symptoms of genital herpes and were requested to present to the study clinic for evaluation of all genitourinary and orolabial signs and symptoms during the course of the trial. At visits for symptoms, genital examination was performed to determine whether lesions were present and to record the number and location of lesions and the duration of symptoms. Specimens for culture for HSV were obtained from all symptomatic sites. All data from such visits were recorded on standardized case-report forms and entered in a centralized data base. In addition, the clinical diagnosis at each visit for the evaluation of genital symptoms was recorded. Blood was collected at every scheduled visit and at visits for the evaluation of genital symptoms.
The glycoprotein-subunit vaccine demonstrated no significant efficacy in either clinical trial (9 percent overall calculated efficacy; 95 percent confidence interval, –29 to 36 percent).14 In addition, detailed analyses identified no significant effect of vaccination on either the frequency of clinical signs and symptoms or the subsequent clinical course of genital herpes acquired during the trial. All cases of genital and orolabial herpes that were identified in either study are included in this report.
Definition of the Acquisition of HSV Infection
The acquisition of HSV infection was defined by the demonstration of HSV-1 or HSV-2 seroconversion, a positive culture for HSV, or both. Cultures for HSV were performed at all study sites with the use of standard techniques.15 Serum samples drawn at the time of trial entry and on the date of termination of the study were paired, and the latter samples were tested for the presence of new antibodies to HSV-specific proteins. We reassayed in parallel all serum samples from persons in whom differences from base line in the antibody profile were noted.16-18 The Western blot assay used for these procedures has a specificity of more than 99.5 percent for the detection of HSV-2 antibodies among persons with positive cultures15,17 and more than 96 percent for the detection of past HSV-1 infection among persons with positive cultures for HSV-1. It also is more sensitive than any other currently used assay for the detection of recent HSV-2 infection.17-20 Of the 178 persons in whom HSV infection had been identified in the initial screening, 174 were confirmed to have seroconversion with respect to either HSV-1 or HSV-2 through the examination of sequential serum samples. These 174 persons constituted the group of patients with newly acquired HSV infection.17-19,21
The date of the first positive culture was considered the date of acquisition of symptomatic infection unless there was an earlier date of seroconversion. For asymptomatic disease, the midpoint between the last negative assay and the first positive sample was used as the date of acquisition. Chart review was performed in a blinded manner for all persons reporting genitourinary or oropharyngeal symptoms and for all 174 persons with seroconversion at the conclusion of the trials.
Statistical Analysis
The log-rank test was used to compare the distribution of times to the acquisition of HSV-2 infection between men and women and between persons who were seropositive and those who were seronegative for HSV-1 at study entry. The Cox proportional-hazards regression model was used to compute the relative risk of acquiring HSV-1 or HSV-2 infection. Relative risk was estimated by the exponential function of λ, where λ was the coefficient from the Cox model, with sex (or HSV-1 serologic status at entry) as the only independent variable. The 95 percent confidence interval for the relative risk was calculated in a similar fashion, with the use of the upper and lower 95 percent confidence limits for λ. Statistical analyses were performed with SAS software (SAS Institute, Cary, N.C.). All reported P values are two-sided.
Results
Characteristics of the Study Participants
Of the 2393 persons enrolled, 1646 were men and 747 were women. At entry, 1508 persons had HSV-1 antibodies and 885 were seronegative for both HSV-1 and HSV-2. All but 2 of the 2393 persons had subsequent serum samples that could be evaluated by Western blot analysis. These two persons (both men) were initially seronegative for both HSV-1 and HSV-2. The remaining 2391 persons were followed prospectively for a total of 3016 person-years. The demographic characteristics of the participants who acquired HSV infection did not differ significantly from those of the participants who did not have seroconversion (Table 1Table 1
Demographic and Serologic Characteristics of the Study Participants Who Acquired New Herpes Simplex Virus Infections.).Rates of Acquisition of HSV-1 and HSV-2 Infection
During the trials, 155 new cases of HSV-2 and 19 new HSV-1 infections were documented. The overall rate of HSV-2 infection averaged 5.1 cases per 100 person-years. The rate of acquisition of HSV-2 infection was significantly higher for women than for men (6.8 vs. 4.4 cases per 100 person-years; relative risk, 1.55; 95 percent confidence interval, 1.11 to 2.11; P<0.01) (Table 2Table 2
Frequency and Rate of Symptomatic and Asymptomatic Herpes Simplex Virus Infection in Adults.). Among white women, the rate of HSV-2 infection was 5.8 cases per 100 person-years, as compared with 11.2 cases per 100 person-years among nonwhite women (relative risk, 0.52; 95 percent confidence interval, 0.34 to 0.94; P=0.03). The comparable rates for white men and nonwhite men were 2.6 and 8.1 cases per 100 person-years, respectively (relative risk, 0.32; 95 percent confidence interval, 0.22 to 0.51; P<0.001). The rates of acquisition were higher among men and women less than 30 years of age (5.3 and 7.6 cases per 100 person-years, respectively) than among those 30 and older (3.5 and 5.5 cases per 100 person-years, P=0.04).Asymptomatic HSV-2 infection was significant-ly more common than symptomatic HSV infection among men (3.0 vs. 1.4 cases per 100 person-years, P<0.001), whereas among women the rates of asymptomatic infection and symptomatic infection were nearly equal (3.8 and 3.0 cases per 100 person-years, respectively). Persons who were seropositive for HSV-1 at study entry were almost as likely to acquire HSV-2 as those who were seronegative for HSV-1 (5.1 vs. 5.2 infections per 100 person-years; relative risk, 0.98; 95 percent confidence interval, 0.70 to 1.34); however, HSV-2 infections among the HSV-1–seropositive participants were more likely to be asymptomatic than symptomatic (3.6 vs. 1.4 cases per 100 person-years, P<0.001). For HSV-1–seronegative subjects, both men and women, the frequency of asymptomatic HSV-2 infection was the same as that of symptomatic HSV-2 infection (2.6 cases per 100 patient-years).
The rate of new HSV-1 infection averaged 1.6 cases per 100 patient-years and was similar for women and men (1.0 and 1.9 cases per 100 person-years, respectively; relative risk, 0.53; 95 percent confidence interval, 0.18 to 1.65).
Clinical Recognition of the New HSV-2 Infections
Among the 155 persons with HSV-2 seroconversion, 57 (37 percent) had genital lesions or other symptoms of infection between the time of screening and the time that HSV-2 seroconversion was confirmed, for a rate of acquisition of symptomatic HSV-2 infection of 1.9 cases per 100 person-years. The median time between the onset of these symptoms or lesions and seroconversion was 56 days (interquartile range, 16 to 121). Of these 57 persons with symptomatic infection, 54 presented to the clinic for medical evaluation (Figure 1Figure 1
Serologically Documented Herpes Simplex Virus Type 2 (HSV-2) Infections.). All three persons who did not initially present with symptoms reported typical lesions at the time of seroconversion, and one of them subsequently presented with a recurrence confirmed by a positive culture.Forty-seven (87 percent) of the 54 participants who presented for evaluation were given a diagnosis of genital HSV disease. Of these 47, 43 had typical signs and symptoms, including genital pain, papules, pustules, vesicles, ulcers, crusts, and fissures. The other four cases of genital herpes, involving two women with genital pain only and two men with urethral discharge, were diagnosed clinically and were included as cases because the results of the screening cultures specified by the protocol were positive. HSV-2 was isolated from lesions in 41 (87 percent) of the 47 persons who presented with clinically recognized signs and symptoms of herpes (Figure 1).
During follow-up, two of the six persons with clinically diagnosed genital herpes who initially had negative cultures subsequently had HSV-2 isolated from a recurrent genital lesion. In addition, one of seven persons who became positive for HSV-2 who were not considered to have herpes at the initial presentation (Figure 1) subsequently had a culture-positive recurrence.
Thus, 41 of the 57 persons with symptomatic HSV-2 seroconversion had positive cultures at the time of their initial presentation to the clinic, and an additional 4 had positive cultures at the time of recurrence. Altogether, at some point during the study, 45 of the 57 persons (79 percent) who had genital symptoms and lesions in association with their seroconversion to HSV-2 had positive HSV-2 cultures.
Seven persons who became positive for HSV-2 presented with symptoms without external genital lesions. None of these seven were initially given a diagnosis of HSV-2, although one was subsequently given such a diagnosis at the time of the first recognized recurrence. One woman, hospitalized for aseptic meningitis and cystitis, had HSV-2 DNA detected in her cerebrospinal fluid by the polymerase chain reaction and had seroconversion by 111 days after the onset of symptoms. Another woman had 11 days of dysuria accompanied by radicular pain on the left side of vertebral bodies L2 and L3. She became positive for HSV-2 within 45 days after the onset of these symptoms. On follow-up, she reported recurrent episodes of genital pain and vaginal numbness during which HSV-2 was isolated. Four men were given a diagnosis of nonchlamydial, nongonococcal urethritis, of whom three were given concomitant diagnoses of penile dermatitis and pubic folliculitis. The seventh person, a woman, had fever, malaise, myalgias, and a purulent vaginal discharge without external genital lesions. These last five persons had had seroconversion by the time of the first available serum sample after the resolution of their symptoms (median, 36 days). The seven cases were classified as nonlesional HSV-2 infections, since urethritis, aseptic meningitis, and cervicitis are well-recognized complications of the first episodes of HSV infection.7,8
Natural History of Asymptomatic HSV-2 Infection
Asymptomatic HSV-2 seroconversion was defined as the absence of any reported or clinically confirmed genital lesions between the time of screening and the time of seroconversion. Of the 155 persons who acquired HSV-2 infection, 98 had asymptomatic seroconversion (63 men and 35 women). The frequency of asymptomatic seroconversion was 2.1 times as high as that of symptomatic seroconversion among men, and 2.6 times as high among HSV-1–seropositive persons (Table 2).
Eighty-five of the 98 persons with asymptomatic HSV-2 seroconversion were prospectively followed for at least 45 days after the date of their first HSV-2–positive serologic test (median number of days of follow-up, 351; interquartile range, 223 to 510). Of these 85 persons, 13 (15 percent) had genital lesions at some later time during follow-up (incidence, 17 per 100 person-years) (Figure 1). Nine of these 13 episodes (69 percent) were clinically diagnosed as genital herpes. Diagnoses recorded for the other four episodes included molluscum contagiosum in a woman in whom ulcerative genital lesions were also found, perineal skin fissure in another woman, papular penile dermatitis in a man in whom ulcerative lesions were also found, and nongonococcal urethritis in another man.
The Predictive Value of a Clinical Diagnosis of Genital Herpes
Of the 155 persons who acquired HSV-2 infection, 58 (37 percent) received a clinical diagnosis of genital herpes during the course of the trial; 47 had contemporaneous seroconversion, 1 had a subsequent lesional recurrence, and in 10 infection was recognized at the first recurrence. Two additional persons had typical lesions for which they did not present for examination but which were classified by the investigator as consistent with herpes. Therefore, a total of 60 cases were considered to be true positives after clinical evaluation.
Fourteen persons were given an incorrect diagnosis of genital herpes — that is, they were given a clinical diagnosis of infection, but all had negative cultures for HSV and no evidence of HSV-2 or HSV-1 seroconversion, despite at least six months of follow-up. Among the 74 persons given a clinical diagnosis of genital HSV-2 during the study, therefore, 60 had true positive test results and 14 had false positive results (ratio of true positives to false positives, 4:1). Thus, 60 persons with symptomatic HSV-2 infection among a total of 155 persons with HSV-2 seroconversion were identified, yielding a sensitivity of 39 percent for the clinical diagnosis of HSV-2 infection and a specificity of 99 percent. The positive predictive value of a clinical diagnosis of genital herpes was 81 percent (60 of 74 symptomatic cases were correctly identified). Since the rate of acquisition of genital herpes was relatively low in this group of patients, the negative predictive value was quite high (96 percent; 2222 of 2317 persons who did not have symptoms were correctly identified).20
Newly Acquired HSV-1 Infection Manifested as Genital Herpes
HSV-1 infection, defined as the isolation of HSV-1 from cultures of the genital tract or seroconversion to HSV-1 between the time of study entry and the time the last follow-up serum sample was obtained, occurred in 19 of the 883 originally seronegative study participants for whom samples were available (2.2 percent). The overall rate of HSV-1 infection was 1.6 cases per 100 person-years. Four of the 19 persons were women and 15 were men (1.0 vs. 1.9 cases per 100 person-years, P not significant).
Of the 19 persons with primary HSV-1 infection, 6 (32 percent) had genital lesions associated with seroconversion. HSV-1 was isolated from the genital lesions of five of these six persons. The sixth person was given a diagnosis of penile fungal dermatitis, but he had seroconversion within 30 days after onset (he thus represented a false negative diagnosis of genital HSV-1). During a median of 266 days of follow-up, only one of the six persons with symptomatic genital HSV-1 infection reported a subsequent genital recurrence. An additional six persons with documented HSV-1 seroconversion reported either orolabial lesions or pharyngitis. Orolabial HSV-1 infection was clinically diagnosed in three persons; the other three had pharyngitis, including one who underwent a tonsillectomy. The remaining seven persons with HSV-1 seroconversion reported no signs or symptoms (i.e., they were asymptomatic). Thus, the rates of newly acquired genital and oropharyngeal HSV-1 infection were both 0.5 case per 100 person-years.
Discussion
This prospective study defines the natural history of newly acquired symptomatic and asymptomatic HSV infection in sexually active adults. Of the 155 cases of newly acquired HSV-2 infection, 57 (37 percent) were associated with clinically symptomatic disease, which contrasts with the 9 percent in the second National Health and Nutrition Examination Survey and the 15 to 25 percent in other serologic studies.2,5 Over 75 percent of the incident cases of symptomatic HSV-2 were associated with lesions of the skin and mucous membranes of the genital tract. However, 13 percent of those who presented with symptomatic HSV-2 had conditions that were not immediately suggestive of herpes, such as cystitis, meningitis, urethritis, and cervicitis. Although this is a small proportion of the total number of cases, the large number of HSV-2 seroconversions that occur in the United States yearly (about 750,000) indicate that these “atypical” presentations will be seen in most clinical practices.
In addition, clinical disease subsequently developed in 15 percent of the persons with asymptomatic seroconversion on follow-up. This percentage represents the minimal number of cases, since it is likely that the percentage would increase with additional prospective follow-up. The observation that seroconversion can precede symptomatic disease is important for the management of genitourinary lesions. Persons with newly recognized disease often assume that they acquired the infection very recently, not months or years earlier.22,23 These data confirm that the detection of HSV-2–specific antibodies at the time of the first presentation with genital lesions may be a useful way to distinguish between past and newly acquired HSV-2 infection.22,23
We also documented a high frequency of genital HSV-1 infection among those with seroconversion to HSV-1. Several studies have described the increasing prevalence of genital HSV-1.24-26 Since the study participants were selected at least in part on the basis of their sexual activity, the frequency of genital HSV-1 infections in this group may differ from that in other populations. However, the equal incidence rates of symptomatic genital HSV-1 and oropharyngeal HSV-1 indicate that sexually active people need counseling about the risk of oral–genital contact, especially during pregnancy.27,28
Our data have several implications for programs to prevent HSV infection. As was noted in previous seroepidemiologic studies, acquisition of HSV-2 was more frequent among women than among men and among nonwhites than among whites.2 The background seroprevalence of HSV-2 of sexual partners may be one explanation for these differences. Sex and past HSV-1 infection had important effects on the presentation of HSV disease. Men were significantly more likely to acquire HSV-2 asymptomatically than were women. Other studies have shown that nearly all asymptomatic HSV-2–seropositive persons, both men and women, shed virus in the genital region.9,29 The higher rate of asymptomatic infection in men may be a factor in the higher rate of male-to-female (as compared with female-to-male) transmission of HSV-2.9,30 Among HSV-seronegative persons, about half of new infections were symptomatic and half were asymptomatic. Previous HSV-1 infection did not reduce the frequency of acquisition of HSV-2 infection, but it did markedly increase the frequency of seroconversion to asymptomatic HSV-2. These data suggest that vaccination with heterotypic antigens might be expected to reduce the incidence of symptomatic HSV-2 disease but not the incidence of infection.
The results of our study also demonstrate the value of type-specific serologic testing for HSV in the diagnosis and clinical management of HSV infection. Even among experienced clinicians following patients in a clinical trial of herpes infection, genital herpes was both underdiagnosed and overdiagnosed. Although cell cultures were useful in identifying infection in persons with skin lesions, serologic assays provided the critical diagnostic confirmation of the “atypical” syndromes and identified the persons with initial asymptomatic seroconversion who had subsequent recurrences.
In summary, incident cases of HSV infection are often symptomatic. Although sex, socioeconomic status, and access to health care professionals skilled in the diagnosis of genital herpes may influence the degree to which this infection is recognized clinically, the clinical spectrum of newly acquired HSV infections was similar in all the clinic populations we studied. Clinical presentation without lesions and acquisition of asymptomatic HSV, followed by clinical reactivation of the disease, were common. Among sexually active adults, new genital HSV-1 infections are as common as new oropharyngeal HSV-1 infections. Laboratory assays that define the type of HSV by viral isolation or serologic screening tests are often needed to ensure an accurate diagnosis.
Dr. Langenberg and Ms. Leong were employees of Chiron during the study.
We are indebted to the members of the study staff at the participating institutions for their careful attention to data collection, and to Nancy Coomer and Brenda Rae Marshall for assistance with the preparation of the manuscript.
Source Information
From Chiron, Emeryville, Calif. (A.G.M.L., W.P.L.); the University of Washington, Seattle (L.C., R.L.A); and the National Institutes of Health, Bethesda, Md. (S.E.S.).
Address reprint requests to Dr. Corey at 1100 Fairview Ave. N. (D3-100), Seattle, WA 98109.
Other members of the Chiron HSV Vaccine Study Group are listed in the Appendix.
Appendix
Other members of the Chiron HSV Vaccine Study were as follows: J.M. Douglas, Jr., Denver Disease Control Service, Denver; H.H. Handsfield, Harborview Medical Center, Seattle; T. Warren and L. Marr, Westover Heights Clinic, Portland, Oreg.; S. Tyring, University of Texas Medical Branch, Galveston; R. DiCarlo and D. Martin, Louisiana State University, New Orleans; A. Rompalo and J. Zenilman, Johns Hopkins University, Baltimore; A.A. Adimora, University of North Carolina School of Medicine, Chapel Hill; P. Leone, Wake County Health Department, Raleigh, N.C.; A. Wald and L. Corey, University of Washington, Seattle; W. McCormack and M. Feminella, State University of New York Health Science Center, Brooklyn; R. Kee and J. Schwebke, Chicago Department of Health, Chicago; E. Sandstrom and H. Carlberg, Karolinska Institute, Stockholm, Sweden; K. Fife, University of Indiana, Indianapolis; E.W. Hook, University of Alabama, Birmingham; S. Sacks, Viridae Clinical Sciences, Vancouver, B.C., Canada; K. McKee, Fort Bragg, N.C.; P. Olson and S. Brodine, Naval Health Research Center, San Diego, Calif.; C. Miller and D. Campbell, Deaconess Health System, St. Louis; K. Workowski, Emory University, Atlanta; K. Beutner, Solano Dermatology Associates, Vallejo, Calif.; G. Mertz, University of New Mexico, Albuquerque; A. Mindel, Sydney Sexual Health Centre, Sydney, Australia; C. Prober and M.A. Carmark, Stanford University, Palo Alto, Calif.; J. Bingham and E. Fox, St. Thomas' Hospital, London; M. Reitano and J. Stern, Riverside Medical Associates, New York; R. Kost, P. Hohman, and S.E. Straus, National Institutes of Health, Bethesda, Md.; T. Rudolph, Detroit Department of Public Health, Detroit; and R. Murphy, Northwestern University, Chicago.
- References
References
1
Nahmias AJ ,Lee FK ,Beckman-Nahmias S . Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990;69:19-36
Medline2
Fleming DT ,McQuillan GM ,Johnson RE , et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-1111
Full Text | Web of Science | Medline3
Schomogyi M ,Wald A ,Corey L . Herpes simplex virus-2 infection: an emerging disease? Infect Dis Clin North Am 1998;12:47-61
CrossRef | Web of Science | Medline4
Langenberg A ,Benedetti J ,Jenkins J ,Ashley R ,Winter C ,Corey L . Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic“ herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-887
Web of Science | Medline5
Siegel D ,Golden E ,Washington AE , et al. Prevalence and correlates of herpes simplex infections: the population-based AIDS in Multiethnic Neighborhoods Study. JAMA 1992;268:1702-1708
CrossRef | Web of Science | Medline6
Cowan FM ,Johnson AM ,Ashley R ,Corey L ,Mindel A . Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis 1996;174:470-475
CrossRef | Web of Science | Medline7
Corey L ,Adams HG ,Brown ZA ,Holmes KK . Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983;98:958-972
Web of Science | Medline8
Whitley RJ, Gnann JW Jr. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993:69-105.
9
Wald A ,Zeh J ,Selke S ,Ashley RL ,Corey L . Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-775
Full Text | Web of Science | Medline10
Holmes KK ,Handsfield HH ,Wang SP , et al. Etiology of nongonococcal urethritis. N Engl J Med 1975;292:1199-1205
Full Text | Web of Science | Medline11
Koutsky LA ,Stevens CE ,Holmes KK , et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326:1533-1539
Full Text | Web of Science | Medline12
Venot C ,Beby A ,Bourgoin A ,Giraudeau G ,Becq-Giraudon B ,Agius G . Genital recurrent infection occurring 6 months after meningitis due to the same herpes simplex virus type 2 (HSV-2) strain evidence by restriction endonuclease analysis. J Infect 1998;36:233-235
CrossRef | Web of Science | Medline13
Schlesinger Y ,Tebas P ,Gaudreault-Keener M ,Buller RS ,Storch GA . Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995;20:842-848
CrossRef | Web of Science | Medline14
Corey L ,Langenberg AGM ,Ashley R , et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999;282:331-340
CrossRef | Web of Science | Medline15
Ashley R. Herpes simplex virus. In: Lennette EH, Lennette DA, Lennette ET, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 7th ed. Washington, D.C.: American Public Health Association, 1995:375-95.
16
Safrin S ,Arvin AM ,Mills J ,Ashley R . Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol 1992;30:1312-1314
Web of Science | Medline17
Ashley R ,Cent A ,Maggs V ,Nahmias A ,Corey L . Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991;115:520-526
Web of Science | Medline18
Ashley RL ,Eagleton M ,Pfeiffer N . Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J Clin Microbiol 1999;37:1632-1633
Web of Science | Medline19
Ashley RL ,Militoni J ,Lee F ,Nahmias A ,Corey L . Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26:662-667
Web of Science | Medline20
Weiss NS. Clinical epidemiology: the study of the outcome of illness. Vol. 11 of Monographs in epidemiology and biostatistics. New York: Oxford University Press, 1986:14-32.
21
Ashley RL ,Wu L ,Pickering JW ,Tu MC ,Schnorenberg L . Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998;36:294-295
Web of Science | Medline22
Bernstein DI ,Lovett MA ,Bryson YJ . Serologic analysis of first-episode nonprimary genital herpes simplex virus infection: presence of type 2 antibody in acute serum samples. Am J Med 1984;77:1055-1060
CrossRef | Web of Science | Medline23
Diamond C ,Selke S ,Ashley R ,Benedetti J ,Corey L . Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis 1999;26:221-225
CrossRef | Web of Science | Medline24
Hashido M ,Lee FK ,Nahmias AJ , et al. An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays. Epidemiol Infect 1998;120:179-186
CrossRef | Web of Science | Medline25
Puthavathana P ,Kanyok R ,Horthongkham N ,Roongpisuthipong A . Prevalence of herpes simplex virus infection in patients suspected of genital herpes; and virus typing by type specific fluorescent monoclonal antibodies. J Med Assoc Thai 1998;81:260-264
Medline26
Andersson-Ellstrom A ,Svennerholm B ,Forssman L . Prevalence of antibodies to herpes simplex virus types 1 and 2, Epstein-Barr virus and cytomegalovirus in teenage girls. Scand J Infect Dis 1995;27:315-318
CrossRef | Web of Science | Medline27
Cone RW ,Hobson AC ,Brown Z , et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA 1994;272:792-796
CrossRef | Web of Science | Medline28
Brown ZA ,Selke S ,Zeh J , et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-515
Full Text | Web of Science | Medline29
Wald A ,Corey L ,Cone R ,Hobson A ,Davis G ,Zeh J . Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1092-1097
CrossRef | Web of Science | Medline30
Mertz GJ ,Benedetti J ,Ashley R ,Selke SA ,Corey L . Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202
Web of Science | Medline
- Citing Articles (117)
Citing Articles
1
Nicholas J. Wagoner, Edward W. Hook. (2012) Herpes Diagnostic Tests and Their Use. Current Infectious Disease Reports
CrossRef2
Stefan Palmason, Francisco M. Marty, Nathaniel S. Treister. (2011) How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?. Oral and Maxillofacial Surgery Clinics of North America 23:4, 579-599
CrossRef3
Prasada Raju V. N. K. V. Vetukuri, Ravindra Vedantham, Vijayavitthal Thippannachar Mathad, Pratap Reddy Padi, Vijaya Anand Ramasamy. (2011) A Concise Route to Valacyclovir Hydrochloride. Helvetica Chimica Acta 94:4, 592-596
CrossRef4
W. Phipps, M. Saracino, A. Magaret, S. Selke, M. Remington, M.-L. Huang, T. Warren, C. Casper, L. Corey, A. Wald. (2011) Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode. Journal of Infectious Diseases 203:2, 180-187
CrossRef5
C Gardella, Z Brown. (2011) Prevention of neonatal herpes. BJOG: An International Journal of Obstetrics & Gynaecology 118:2, 187-192
CrossRef6
Melissa A. Habel, Patricia J. Dittus, Christine J. De Rosa, Emily Q. Chung, Peter R. Kerndt. (2010) Daily Participation in Sports and Students' Sexual Activity. Perspectives on Sexual and Reproductive Health 42:4, 244-250
CrossRef7
Laith J. Abu-Raddad, Joshua T. Schiffer, Rhoda Ashley, Ghina Mumtaz, Ramzi A. Alsallaq, Francisca Ayodeji Akala, Iris Semini, Gabriele Riedner, David Wilson. (2010) HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics 2:4, 173-182
CrossRef8
Nienke J Veldhuijzen, Peter JF Snijders, Peter Reiss, Chris JLM Meijer, Janneke HHM van de Wijgert. (2010) Factors affecting transmission of mucosal human papillomavirus. The Lancet Infectious Diseases 10:12, 862-874
CrossRef9
Vinit B. Mahajan, Edwin M. Stone. (2010) Patients With an Acute Zonal Occult Outer Retinopathy–like Illness Rapidly Improve With Valacyclovir Treatment. American Journal of Ophthalmology 150:4, 511-518
CrossRef10
Robert Horowitz, Sara Aierstuck, Elizabeth A. Williams, Bernette Melby. (2010) Herpes Simplex Virus Infection in a University Health Population: Clinical Manifestations, Epidemiology, and Implications. Journal of American College Health 59:2, 69-74
CrossRef11
Nicholas Nguyen, Craig N. Burkhart, Craig G. Burkhart. (2010) Review: Identifying potential pitfalls in conventional herpes simplex virus management. International Journal of Dermatology 49:9, 987-993
CrossRef12
Anna Wald, Patti E Gravitt, Rhoda A Morrow. 2010. Sexually Transmitted Infections. , 370-382.
CrossRef13
Damjan S Nikolic, Vincent Piguet. (2010) Vaccines and Microbicides Preventing HIV-1, HSV-2, and HPV Mucosal Transmission. Journal of Investigative Dermatology 130:2, 352-361
CrossRef14
Anthony G. Brazzale, Darren B. Russell, Anthony L. Cunningham, Janette Taylor, William J. H. McBride. (2010) Seroprevalence of herpes simplex virus type 1 and type 2 among the Indigenous population of Cape York, Far North Queensland, Australia. Sexual Health 7:4, 453
CrossRef15
Gargi Dasgupta, Anthony B Nesburn, Steven L Wechsler, Lbachir BenMohamed. (2010) Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiology 5:1, 1-4
CrossRef16
Peter Norberg. (2010) Divergence and genotyping of human α-herpesviruses: An overview. Infection, Genetics and Evolution 10:1, 14-25
CrossRef17
Joshua T. Schiffer, Lawrence Corey. (2009) New concepts in understanding genital herpes. Current Infectious Disease Reports 11:6, 457-464
CrossRef18
Rossen Donev, Martin Kolev, Bruno Millet, Johannes Thome. (2009) Neuronal death in Alzheimer’s disease and therapeutic opportunities. Journal of Cellular and Molecular Medicine 13:11-12, 4329-4348
CrossRef19
Işıl Maral, Aydan Biri, Ümit Korucuoğlu, Coşkun Bakar, Meltem Çırak, M. Ali Bumin. (2009) Seroprevalences of herpes simplex virus type 2 and Chlamydia trachomatis in Turkey. Archives of Gynecology and Obstetrics 280:5, 739-743
CrossRef20
Richard Brans, Natali V Akhrameyeva, Feng Yao. (2009) Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1. Journal of Investigative Dermatology 129:10, 2470-2479
CrossRef21
Juliana Marotti, Ana Cecília Correa Aranha, Carlos De Paula Eduardo, Martha Simões Ribeiro. (2009) Photodynamic Therapy Can Be Effective as a Treatment for Herpes Simplex Labialis. Photomedicine and Laser Surgery 27:2, 357-363
CrossRef22
Anna M. Foss, Peter T. Vickerman, Zaid Chalabi, Philippe Mayaud, Michel Alary, Charlotte H. Watts. (2009) Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty. Bulletin of Mathematical Biology 71:3, 720-749
CrossRef23
Irene E Aga, Lisa M Hollier. (2009) Managing genital herpes infections in pregnancy. Women's Health 5:2, 165-174
CrossRef24
X Zhang, A A Chentoufi, G Dasgupta, A B Nesburn, M Wu, X Zhu, D Carpenter, S L Wechsler, S You, L BenMohamed. (2009) A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunology 2:2, 129-143
CrossRef25
Yasufumi Doi, Toshiharu Ninomiya, Jun Hata, Koji Yonemoto, Yumihiro Tanizaki, Hisatomi Arima, Ying Liu, Mahbubur Rahman, Misuo Iida, Yutaka Kiyohara. (2009) Seroprevalence of Herpes Simplex Virus 1 and 2 in a Population-Based Cohort in Japan. Journal of Epidemiology 19:2, 56-62
CrossRef26
A. Svensson, A.-M. H. Bergin, G.-B. Lowhagen, P. Tunback, L. Bellner, L. Padyukov, K. Eriksson. (2008) A 3'-untranslated region polymorphism in the TBX21 gene encoding T-bet is a risk factor for genital herpes simplex virus type 2 infection in humans. Journal of General Virology 89:9, 2262-2268
CrossRef27
MARIA F. GALLO, LEE WARNER, MAURIZIO MACALUSO, KATHERINE M. STONE, ILENE BRILL, MICHAEL E. FLEENOR, EDWARD W. HOOK, HARLAND D. AUSTIN, FRANCIS K. LEE, ANDRé J. NAHMIAS. (2008) Risk Factors for Incident Herpes Simplex Type 2 Virus Infection Among Women Attending a Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases 35:7, 679-685
CrossRef28
Julia A. Schillinger, Christy M. McKinney, Renu Garg, R Charon Gwynn, Kellee White, Francis Lee, Susan Blank, Lorna Thorpe, Thomas Frieden. (2008) Seroprevalence of Herpes Simplex Virus Type 2 and Characteristics Associated With Undiagnosed Infection: New York City, 2004. Sexually Transmitted Diseases 35:6, 599-606
CrossRef29
Richard Rupp, David I Bernstein. (2008) The potential impact of a prophylactic herpes simplex vaccine. Expert Opinion on Emerging Drugs 13:1, 41-52
CrossRef30
David M. Koelle, Lawrence Corey. (2008) Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annual Review of Medicine 59:1, 381-395
CrossRef31
David M. Koelle, Tracy L. Bergemann. (2008) Doctor, Why Is My Herpes So Bad? The Search Continues. The Journal of Infectious Diseases 197:3, 331-334
CrossRef32
Tara Lee Frenkl, Jeannette Potts. (2008) Sexually Transmitted Infections. Urologic Clinics of North America 35:1, 33-46
CrossRef33
Carlos T. Da Ros, Caio da Silva Schmitt. (2008) Global epidemiology of sexually transmitted diseases. Asian Journal of Andrology 10:1, 110-114
CrossRef34
H.F. Rabenau, H.W. Doerr. (2008) Genitaler Herpes und HSV-Transmission bei HIV-Patienten. Der Hautarzt 59:1, 11-17
CrossRef35
Rachna Gupta, Terri Warren, Anna Wald. (2007) Genital herpes. The Lancet 370:9605, 2127-2137
CrossRef36
Katherine M Coyne, Simon E Barton. (2007) Epidemiology of sexually transmitted infections. Expert Review of Obstetrics & Gynecology 2:6, 803-816
CrossRef37
Mahnaz Fatahzadeh, Robert A. Schwartz. (2007) Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the American Academy of Dermatology 57:5, 737-763
CrossRef38
Fujie Xu, Francis K. Lee, Rhoda A. Morrow, Maya R. Sternberg, Kristina E. Luther, Gary Dubin, Lauri E. Markowitz. (2007) Seroprevalence of Herpes Simplex Virus Type 1 in Children in the United States. The Journal of Pediatrics 151:4, 374-377
CrossRef39
Sook-Bin Woo, Stephen J. Challacombe. (2007) Management of recurrent oral herpes simplex infections. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 103, S12.e1-S12.e18
CrossRef40
John R. Williams, Jamie C. Jordan, E Anne Davis, Geoffrey P. Garnett. (2007) Suppressive Valacyclovir Therapy: Impact on the Population Spread of HSV-2 Infection. Sexually Transmitted Diseases 34:3, 123-131
CrossRef41
Anders Strand. (2007) Diagnosis of genital herpes: the role and place of HSV testing in clinical practice. European Clinics in Obstetrics and Gynaecology 2:4, 181-189
CrossRef42
Fujie Xu, Lauri E. Markowitz, Sami L. Gottlieb, Stuart M. Berman. (2007) Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. American Journal of Obstetrics and Gynecology 196:1, 43.e1-43.e6
CrossRef43
Outi Kortekangas-Savolainen, Tytti Vuorinen. (2007) Trends in Herpes Simplex Virus Type 1 and 2 Infections Among Patients Diagnosed With Genital Herpes in a Finnish Sexually Transmitted Disease Clinic, 1994???2002. Sexually Transmitted Diseases 34:1, 37-40
CrossRef44
David C Ritterband. (2006) Herpes simplex keratitis: classification, pathogenesis and therapy. Expert Review of Ophthalmology 1:2, 241-256
CrossRef45
Alan T. N. Tita, William A. Grobman, Dwight J. Rouse. (2006) Antenatal Herpes Serologic Screening. Obstetrics & Gynecology 108:5, 1247-1253
CrossRef46
Jeffrey J Meffert. (2006) Sexually transmitted infections and HIV control efforts. Expert Review of Dermatology 1:5, 655-665
CrossRef47
Claire Ryan, George Kinghorn. (2006) Clinical assessment of assays for diagnosis of herpes simplex infection. Expert Review of Molecular Diagnostics 6:5, 767-775
CrossRef48
Ilham Bettahi, Xiuli Zhang, Rasha E. Afifi, Lbachir Benmohamed. (2006) Protective Immunity to Genital Herpes Simplex Virus Type 1 and Type 2 Provided by Self-Adjuvanting Lipopeptides That Drive Dendritic Cell Maturation and Elicit a Polarized Th1 Immune Response. Viral Immunology 19:2, 220-236
CrossRef49
Jay S. Pepose, Tammie L. Keadle, Lynda A. Morrison. (2006) Ocular Herpes Simplex: Changing Epidemiology, Emerging Disease Patterns, and the Potential of Vaccine Prevention and Therapy. American Journal of Ophthalmology 141:3, 547-557.e2
CrossRef50
Rochelle R. Torgerson, Mary L. Marnach, Alison J. Bruce, Roy S. Rogers. (2006) Oral and vulvar changes in pregnancy. Clinics in Dermatology 24:2, 122-132
CrossRef51
Betty A. Donoval, Douglas J. Passaro, Jeffrey D. Klausner. (2006) The Public Health Imperative for a Neonatal Herpes Simplex Virus Infection Surveillance System. Sexually Transmitted Diseases 33:3, 170-174
CrossRef52
A. Kolokotronis, S. Doumas. (2006) Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis. Clinical Microbiology and Infection 12:3, 202-211
CrossRef53
Meghna Ramaswamy, Caroline Sabin, Candice McDonald, Melvyn Smith, Chris Taylor, Anna Maria Geretti. (2006) Herpes Simplex Virus Type 2 (HSV-2) Seroprevalence at the Time of HIV-1 Diagnosis and Seroincidence After HIV-1 Diagnosis in an Ethnically Diverse Cohort of HIV-1-Infected Persons. Sexually Transmitted Diseases 33:2, 96-101
CrossRef54
David B. Lewis, Christopher B. Wilson. 2006. Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. , 87-210.
CrossRef55
Lewis J. Haddow, Adrian Mindel. (2006) Genital herpes vaccines—cause for cautious optimism. Sexual Health 3:1, 1
CrossRef56
Carolyn Gardella, Zane Brown, Anna Wald, Stacy Selke, Judy Zeh, Rhoda Ashley Morrow, Lawrence Corey. (2005) Risk factors for herpes simplex virus transmission to pregnant women: A couples study. American Journal of Obstetrics and Gynecology 193:6, 1891-1899
CrossRef57
Matthew R. Golden, Rhoda Ashley-Morrow, Paul Swenson, Wayne R. Hogrefe, H Hunter Handsfield, Anna Wald. (2005) Herpes Simplex Virus Type 2 (HSV-2) Western Blot Confirmatory Testing Among Men Testing Positive for HSV-2 Using the Focus Enzyme-Linked Immunosorbent Assay in a Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases 32:12, 771-777
CrossRef58
Zane A. Brown, Carolyn Gardella, Anna Wald, Rhoda Ashley Morrow, Lawrence Corey. (2005) Genital Herpes Complicating Pregnancy. Obstetrics & Gynecology 106:4, 845-856
CrossRef59
David Bernstein. (2005) Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Review of Vaccines 4:5, 615-627
CrossRef60
Denis Malvy, Bruno Halioua, Florian Lan??on, Ali Rezvani, Sandrine Bertrais, Bruno Chanzy, Michel Daniloski, Khaled Ezzedine, Jean-Elie Malkin, Patrice Morand, Cecile De Labareyre, Serge Hercberg, Abdelkader El Hasnaoui. (2005) Epidemiology of Genital Herpes Simplex Virus Infections in a Community-Based Sample in France: Results of the HERPIMAX Study. Sexually Transmitted Diseases 32:8, 499-505
CrossRef61
Carolyn Gardella, Zane A. Brown, Anna Wald, Rhoda Ashley Morrow, Stacy Selke, Elizabeth Krantz, Lawrence Corey. (2005) Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor. Obstetrics & Gynecology 106:2, 268-274
CrossRef62
Nancy A. Danke, David M. Koelle, William W. Kwok. (2005) Persistence of Herpes Simplex Virus Type 2 VP16-Specific CD4+ T Cells. Human Immunology 66:7, 777-787
CrossRef63
Raj Patel, Anne Rompalo. (2005) Managing Patients with Genital Herpes and their Sexual Partners. Infectious Disease Clinics of North America 19:2, 427-438
CrossRef64
Terri Warren, Charles Ebel. (2005) Counseling the Patient who has Genital Herpes or Genital Human Papillomavirus Infection. Infectious Disease Clinics of North America 19:2, 459-476
CrossRef65
Geoffrey P. Garnett. (2005) Role of Herd Immunity in Determining the Effect of Vaccines against Sexually Transmitted Disease. The Journal of Infectious Diseases 191:s1, S97-S106
CrossRef66
Stephen F. Thung, William A. Grobman. (2005) The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus–1 and –2 antibodies. American Journal of Obstetrics and Gynecology 192:2, 483-488
CrossRef67
W. Hellenbrand, W. Thierfelder, B. M
ller-Pebody, O. Hamouda, T. Breuer. (2005) Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997?1998. European Journal of Clinical Microbiology & Infectious Diseases 24:2, 131-135
CrossRef68
Thomas L. Cherpes, Leslie A. Meyn, Sharon L. Hillier. (2005) Cunnilingus and Vaginal Intercourse Are Risk Factors for Herpes Simplex Virus Type 1 Acquisition in Women. Sexually Transmitted Diseases 32:2, 84-89
CrossRef69
P. N. Levett. (2005) Seroprevalence of HSV-1 and HSV-2 in Barbados. Medical Microbiology and Immunology 194:1-2, 105-107
CrossRef70
S. L. Guerry, H. M. Bauer, J. D. Klausner, B. Branagan, P. R. Kerndt, B. G. Allen, G. Bolan. (2005) Recommendations for the Selective Use of Herpes Simplex Virus Type 2 Serological Tests. Clinical Infectious Diseases 40:1, 38-45
CrossRef71
Julia Ann Schillinger, Fujie Xu, Maya Raquel Sternberg, Gregory Lee Armstrong, Francis Kwokshun Lee, Andre Joseph Nahmias, Geraldine Marie McQuillan, Michael Ernest Louis, Lauri Ellen Markowitz. (2004) National Seroprevalence and Trends in Herpes Simplex Virus Type 1 in the United States, 1976???1994. Sexually Transmitted Diseases 31:12, 753-760
CrossRef72
Arun Chakrabarty, Karl Beutner. (2004) Therapy of other viral infections: herpes to hepatitis. Dermatologic Therapy 17:6, 465-490
CrossRef73
L. R. Stanberry, S. L. Rosenthal, L. Mills, P. A. Succop, F. M. Biro, R. A. Morrow, D. I. Bernstein. (2004) Longitudinal Risk of Herpes Simplex Virus (HSV) Type 1, HSV Type 2, and Cytomegalovirus Infections among Young Adolescent Girls. Clinical Infectious Diseases 39:10, 1433-1438
CrossRef74
J Dennis Fortenberry, Gregory D. Zimet, Rebecca Brady, Jingwei Wu, Wanzhu Tu, Katherine M. Stone, Susan L. Rosenthal, David I. Bernstein, Kenneth H. Fife. (2004) Return for Results After Herpes Simplex Virus Type 2 Screening. Sexually Transmitted Diseases 31:11, 655-658
CrossRef75
Lara Strick, Anna Wald. (2004) Type-specific testing for herpes simplex virus. Expert Review of Molecular Diagnostics 4:4, 443-453
CrossRef76
FINN FIL??N, ANDERS STRAND, ANNIKA ALLARD, JONAS BLOMBERG, BJ??RN HERRMANN. (2004) Duplex Real-Time Polymerase Chain Reaction Assay for Detection and Quantification of Herpes Simplex Virus Type 1 and Herpes Simplex Virus Type 2 in Genital and Cutaneous Lesions. Sexually Transmitted Diseases 31:6, 331-336
CrossRef77
M. BOD??US, K. LAFFINEUR, B. KABAMBA-MUKADI, C. HUBINONT, P. BERNARD, P. GOUBAU. (2004) Seroepidemiology of Herpes Simplex Type 2 in Pregnant Women in Belgium. Sexually Transmitted Diseases 31:5, 297-300
CrossRef78
Noreen A. Hynes. (2004) Reducing genital herpes transmission using antiviral therapy. Current Infectious Disease Reports 6:2, 127-128
CrossRef79
Corey, Lawrence, Wald, Anna, Patel, Raj, Sacks, Stephen L., Tyring, Stephen K., Warren, Terri, Douglas, John M. Jr., Paavonen, Jorma, Morrow, R. Ashley, Beutner, Karl R., Stratchounsky, Leonid S., Mertz, Gregory, Keene, Oliver N., Watson, Helen A., Tait, Dereck, Vargas-Cortes, Mauricio, . (2004) Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine 350:1, 11-20
Full Text80
Sabina Hirshfield, Robert H Remien, Imelda Walavalkar, Mary Ann Chiasson. (2004) Crystal Methamphetamine Use Predicts Incident STD Infection Among Men Who Have Sex With Men Recruited Online: A Nested Case-Control Study. Journal of Medical Internet Research 6:4, e41
CrossRef81
P.-Y. Boëlle, F. Fagnani, A.-J. Valleron, B. Detournay, A. El Hasnaoui, B. Halioua, J.-C. Nicolas. (2004) Un modèle épidémiologique de l’herpès génital pour l’évaluation des interventions thérapeutiques et prophylactiques. Annales de Dermatologie et de Vénéréologie 131:1, 17-26
CrossRef82
Dianne Langford, Eliezer Masliah. (2003) The emerging role of infectious pathogens in neurodegenerative diseases. Experimental Neurology 184:2, 553-555
CrossRef83
Jeanne M. Marrazzo, Kathleen Stine, Anna Wald. (2003) Prevalence and Risk Factors for Infection With Herpes Simplex Virus Type-1 and -2 Among Lesbians. Sexually Transmitted Diseases 30:12, 890-895
CrossRef84
Hayley D. Mark, Ashley P. Hanahan, Stacie C. Stender. (2003) Herpes Simplex Virus Type 2: An Update. The Nurse Practitioner 28:11, 34-37
CrossRef85
MICHAEL DAN, OSCAR SADAN, MAREK GLEZERMAN, DAVID RAVEH, ZMIRA SAMRA. (2003) Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Pregnant Women in Israel. Sexually Transmitted Diseases 30:11, 835-838
CrossRef86
Joanne Turner, Oliver C Turner, Nick Baird, Ian M Orme, Christine L Wilcox, Susan L Baldwin. (2003) Influence of increased age on the development of herpes stromal keratitis. Experimental Gerontology 38:10, 1205-1212
CrossRef87
Craig M. Roberts, John R. Pfister, Scott J. Spear. (2003) Increasing Proportion of Herpes Simplex Virus Type 1 as a Cause of Genital Herpes Infection in College Students. Sexually Transmitted Diseases 30:10, 797-800
CrossRef88
T. L. Cherpes, L. A. Meyn, M. A. Krohn, J. G. Lurie, S. L. Hillier. (2003) Association between Acquisition of Herpes Simplex Virus Type 2 in Women and Bacterial Vaginosis. Clinical Infectious Diseases 37:3, 319-325
CrossRef89
Charles Dimitry Abraham, Carlos J. Conde-Glez, Aurelio Cruz-Valdez, Luisa Sánchez-Zamorano, Clara Hernández-Márquez, Eduardo Lazcano-Ponce. (2003) Sexual and Demographic Risk Factors for Herpes Simplex Virus Type 2 According to Schooling Level Among Mexican Youths. Sexually Transmitted Diseases 30:7, 549-555
CrossRef90
THOMAS L. CHERPES, LESLIE A. MEYN, MARIJANE A. KROHN, SHARON L. HILLIER. (2003) Risk Factors for Infection With Herpes Simplex Virus Type 2:. Sexually Transmitted Diseases 30:5, 405-410
CrossRef91
RHODA ASHLEY-MORROW, ELIZABETH KRANTZ, ANNA WALD. (2003) Time Course of Seroconversion by HerpeSelect ELISA After Acquisition of Genital Herpes Simplex Virus Type 1 (HSV-1) or HSV-2. Sexually Transmitted Diseases 30:4, 310-314
CrossRef92
KATHERINE R. TURNER, WILLI McFARLAND, TIMOTHY A. KELLOGG, ERNEST WONG, KIMBERLY PAGE-SHAFER, BRIAN LOUIE, JIM DILLEY, CHARLOTTE K. KENT, JEFFREY KLAUSNER. (2003) Incidence and Prevalence of Herpes Simplex Virus Type 2 Infection in Persons Seeking Repeat HIV Counseling and Testing. Sexually Transmitted Diseases 30:4, 331-334
CrossRef93
Peter Leone. (2003) Type-specific serologic testing for herpes simplex virus-2. Current Infectious Disease Reports 5:2, 159-165
CrossRef94
SAIDI H. KAPIGA, NOEL E. SAM, JOHN F. SHAO, ELISANTE J. MASENGA, BORIS RENJIFO, IREEN E. KIWELU, RACHEL MANONGI, WAFAIE W. FAWZI, MAX ESSEX. (2003) Herpes Simplex Virus Type 2 Infection Among Bar and Hotel Workers in Northern Tanzania. Sexually Transmitted Diseases 30:3, 187-192
CrossRef95
M. Strutt, J. Bailey, M. Tenant-Flowers, D. Graham, M. Zuckerman. (2003) Ethnic variation in type of genital herpes simplex virus infection in a South London genitourinary medicine clinic. Journal of Medical Virology 69:1, 108-110
CrossRef96
Mathijs H Brentjens, Kimberly A Yeung-Yue, Patricia C Lee, Stephen K Tyring. (2003) Recurrent Genital Herpes Treatments and Their Impact on Quality of Life. PharmacoEconomics 21:12, 853-863
CrossRef97
Stanberry, Lawrence R., Spruance, Spotswood L., Cunningham, Anthony L., Bernstein, David I., Mindel, Adrian, Sacks, Stephen, Tyring, Stephen, Aoki, Fred Y., Slaoui, Moncef, Denis, Martine, Vandepapeliere, Pierre, Dubin, Gary, . (2002) Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes. New England Journal of Medicine 347:21, 1652-1661
Full Text98
ANNA MARIA EIS-HÜBINGER, EMMANUEL NYANKIYE, DIDIER MBOUA BITOUNGUI, JEAN NDJOMOU. (2002) Prevalence of Herpes Simplex Virus Type 2 Antibody in Cameroon. Sexually Transmitted Diseases 29:11, 637-642
CrossRef99
Anna Wald, Rhoda Ashley‐Morrow. (2002) Serological Testing for Herpes Simplex Virus (HSV)–1 and HSV‐2 Infection. Clinical Infectious Diseases 35:s2, S173-S182
CrossRef100
Lawrence Corey. (2002) Challenges in Genital Herpes Simplex Virus Management. The Journal of Infectious Diseases 186:s1, S29-S33
CrossRef101
DAVID N. FISMAN, MARC LIPSITCH, EDWARD W. HOOK, SUE J. GOLDIE. (2002) Projection of the Future Dimensions and Costs of the Genital Herpes Simplex Type 2 Epidemic in the United States. Sexually Transmitted Diseases 29:10, 608-622
CrossRef102
Marianne C. Morris, W. John Edmunds, Louise M. Hesketh, Andrew J. Vyse, Elizabeth Miller, Peter Morgan-Capner, David W.G. Brown. (2002) Sero-epidemiological patterns of epstein-barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales. Journal of Medical Virology 67:4, 522-527
CrossRef103
Andwele Mwansasu, Davis Mwakagile, Lars Haarr, Nina Langeland. (2002) Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. Journal of Clinical Virology 24:3, 183-192
CrossRef104
Kimberly A. Yeung-Yue, Mathijs H. Brentjens, Patricia C. Lee, Stephen K. Tyring. (2002) The management of herpes simplex virus infections. Current Opinion in Infectious Diseases 15:2, 115-122
CrossRef105
Robert Snoeck, Erik De Clercq. (2002) New treatments for genital herpes. Current Opinion in Infectious Diseases 15:1, 49-55
CrossRef106
Meir Isacsohn, Zahava Smetana, Zichria Zakai Rones, David Raveh, Yoram Diamant, Arnon Samueloff, Michel Shaya, Ella Mendelson, Paul Slater, Bernard Rudenski, Elchanan Bar On, Abraham Morag. (2002) A sero-epidemiological study of herpes virus type 1 and 2 infection in Israel. Journal of Clinical Virology 24:1-2, 85-92
CrossRef107
Lawrence R. Stanberry, Susan L. Rosenthal. (2002) Genital Herpes Simplex Virus Infection in the Adolescent. Pediatric Drugs 4:5, 291-297
CrossRef108
DAVID M. PATRICK, MEENAKSHI DAWAR, DARREL A. COOK, MEL KRAJDEN, HELEN C. NG, MICHAEL L. REKART. (2001) Antenatal Seroprevalence of Herpes Simplex Virus Type 2 (HSV-2) in Canadian Women. Sexually Transmitted Diseases 28:7, 424-428
CrossRef109
J Peter. (2001) Review of 3200 serially received CSF samples submitted for type-specific HSV detection by PCR in the reference laboratory setting. Molecular and Cellular Probes 15:3, 177-182
CrossRef110
Richard J Whitley, Bernard Roizman. (2001) Herpes simplex virus infections. The Lancet 357:9267, 1513-1518
CrossRef111
EDUARDO LAZCANO-PONCE, JENNIFER S. SMITH, NUBIA MU??OZ, CARLOS J. CONDE-GLEZ, LUIS JUÁREZ-FIGUEROA, AURELIO CRUZ, MAURICIO HERNÁNDEZ. (2001) High Prevalence of Antibodies to Herpes Simplex Virus Type 2 Among Middle-Aged Women in Mexico City, Mexico. Sex Transm Dis 28:5, 270-276
CrossRef112
Debera Jane Thomas. (2001) Sexually Transmitted Viral Infections: Epidemiology and Treatment. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 30:3, 316-323
CrossRef113
GINA SUCATO, CONNIE CELUM, DWYN DITHMER, RHODA ASHLEY, ANNA WALD. (2001) Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. The Pediatric Infectious Disease Journal 20:4, 422-426
CrossRef114
G. B. Löwhagen, P. Tunbäck, K. Anderss. (2001) Recurrent Genital Herpes in a Population Attending a Clinic for Sexually Transmitted Diseases. Acta Dermato-Venereologica 81:1, 35-37
CrossRef115
Thomas J. Liesegang. (2001) Herpes Simplex Virus Epidemiology and Ocular Importance. Cornea 20:1, 1-13
CrossRef116
D.K Oladepo, P.E Klapper, H.S Marsden. (2000) Peptide based enzyme-linked immunoassays for detection of anti-HSV-2 IgG in human sera. Journal of Virological Methods 87:1-2, 63-70
CrossRef117
J HIRSCHMANN. (2000) Antimicrobial prophylaxis in dermatology. Seminars in Cutaneous Medicine and Surgery 19:1, 2-9
CrossRef
